Clinitech, LLC — Department of Health and Human Services SBIR Phase I: 450

Clinitech, LLC — SBIR Phase I award from Department of Health and Human Services.

Amount
$228,721
Agency
Department of Health and Human Services · National Institutes of Health
Program / Phase
SBIR · Phase I
Topic
450
Solicitation
PAR16-410
NAICS
Place of performance
NV
Period
2017-08-20 → 2018-07-31

Description

PROJECT SUMMARY This application for a Phase I SBIR award represents a collaboration between Clinitech LLC and McLean Hospital Harvard Medical School to develop a wearable biosensor for detecting alcohol in the interstitial fluid of humans who have consumed alcohol Excessive use of alcohol accounts for much of the public health burden related to alcohol use disorders including fetal alcohol syndrome fatal motor crashes accidents and homicides On college campuses alone alcohol use results annually in almost deaths sexual assaults injuries and assaults These figures justify the need at many levels to have a wearable device that can help track individualandapos s alcohol consumption in real time A prototype device has already been developed for glucose and the current proposal is aimed at modifying the basic concept to measure alcohol All patents and licenses are in place at Clinitech and the McLean Hospital team has decades of experience in administering alcohol to human volunteers and then measuring blood breath and most recently tissue alcohol levels Thus the two sites are ideal to collaborate on this joint venture and are well poised to initiate this project at a very rapid pace The device named LabPatch alcohol utilizes a novel combination of technology that samples interstitial fluid from just underneath the skin by temporarily disrupting the waterproof stratum corneum epidermal barrier collecting interstitial fluid into a micro chamber within the patch and then applying an electrochemical reaction to measure alcohol concentration The device is unobtrusive looks like an adhesive bandage causes no injury to the skin and its operation cannot be perceived by the person who is wearing it The initial prototype will be wired to a computer and once the detection circuitry is finalized and the calibrations with blood alcohol completed during this proposed Phase I study the next step Phase II would be to reduce the size of the patch even further and add the wireless Bluetooth capability so that measures of blood alcohol levels can be sent directly to a website via a smartphone application This opens a number of major opportunities to provide real time oversight of individualsandapos drinking patterns The research plan will use an iterative approach by which Clinitech will develop the prototypes and then McLean will test them with human subjects who have been given measured amounts of alcohol to consume Parallel samples of interstitial fluid and blood will be tested for alcohol concentration in order to correlate the pharmacokinetic profile of alcohol in these two compartments Full exchange of the data will permit rapid adjustments made on the prototypes so that modified versions can be tested in a timely manner Key milestones for Phase I include design and fabricate the initial prototype LabPatch alcohol device perform initial calibration testing via benchtop studies obtain IRB approval conduct initial human testing share the data for improvements retesting preparation of Phase II application PROJECT NARRATIVE The proposed Phase I SBIR project represents a collaboration between the small business Clinitech LLC and McLean Hospital to develop and refine a wearable unobtrusive biosensor to detect and communicate in real time alcohol in interstitial fluid and test its accuracy against blood alcohol levels in human volunteers